London and Manchester, UK, 09 January 2015: Ximbio (www.ximb.io), an online reagents portal for the life science community which originates from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK, and UMIP, The University of Manchester’s agent for IP commercialisation, announce Ximbio will be exhibiting at The University of Manchester on 20th and 21st January 2015.
Researchers interested in learning how Ximbio can help increase the global visibility of their new and already developed research tools, and help manage requests for those reagents, are invited to contact Dr Melanie Hardman from Ximbio (E: melanie@ximb.io, T: 020 3469 6449 or 07733 220175) to arrange a one-to-one discussion. Alternatively Melanie will be available at the Ximbio exhibition stand on:
Tuesday 20th January at the Michael Smith Building, and on
Wednesday 21st January at the MIB John Garside Building.
Ximbio is an online portal for the life science community to exchange knowledge and trade reagents. Researchers can virtually deposit reagents, to raise their profile and share research globally. The Ximbio community benefits from Ximbio’s existing relationships with more than 100 life science reagents companies. Deposited reagents can be ‘tagged’ with details of the laboratory where they were developed, to make it easier for future users to cite the originating source in publications. Researchers can also use Ximbio to help make an informed decision about where to source aproduct from, and share experiences of using specific reagents with others.
Melanie Hardman, Head of Ximbio, commented: “We are excited to visit The University of Manchester, in collaboration with UMIP. We created Ximbio to be a place where the reagent community can be unified, maximising the visibility and impact of all research reagents and making them more widely and easily available, to help accelerate life science research. We look forward to working with Manchester based researchers.”
Dr. Ed Maughfling, Express Licensing Manager, UMIP, said: “Research reagents represent one of four key product areas (along with software, clinical questionnaires and images) of UMIP’s Express IP portfolio (http://umip.com/what-is-express-ip/). As part of UMIP’s strategy of developing either online sales capability (www.click2go.umip.com) or working with a preferred licensing partner, UMIP and Ximbio hope to work together to identify, disseminate and commercialise research reagents developed at The University of Manchester.”